$ARAY

Accuray director Mika Nishimura will not seek re-election and will leave the board after the 2026 annual meeting. She will continue as Compensation Committee Chair until then. The departure is not due to any disagreement with the company or board, according to the SEC filing.

ACCURAY INC (ARAY) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (a) On October 8, 2026, Mika Nishimura, a Class II director of Accuray Incorporated (the “Company”), informed the Company’s

Accuray (ARAY) stockholders approved financing-related proposals, enabling transactions with TCW Asset Management, including debt exchange, equity investment, and a reverse stock split. The company also appointed Richard A. Meier to its board. The moves aim to strengthen Accuray's financial position and support long-term value creation.

Accuray (ARAY) and Samsung NeuroLogica have partnered to advance volumetric imaging for the CyberKnife System. The collaboration aims to enhance treatment efficiency and decision-making, addressing customer priorities. Key clinicians highlighted the potential benefits for various cancer treatments. The partnership is part of Accuray's strategy to accelerate innovation through targeted collaborations.

Accuray (ARAY) has agreed to an $8 million deal with RaySearch to integrate their technologies, accelerating online adaptive radiation therapy. The collaboration focuses on Accuray's Radixact and CyberKnife platforms, aiming to enhance personalized treatments. Accuray's transformation plan has already exceeded cost and margin improvement targets by $20 million for fiscal 2026. Risks include slow adoption and third-party dependency on RaySearch. Institutional investment in ARAY has increased, wit

RaySearch (STO: RAY B) and Accuray (NASDAQ: ARAY) agreed to expand their collaboration to accelerate online adaptive radiation therapy. Accuray will purchase RayStation licenses worth $8M, recognized as revenue in 2026. The partnership combines Accuray's platforms with RaySearch's software for personalized treatments.

TCW Group Inc increased its stake in Accuray Inc (ARAY) by 8.59 million shares at $0.2309 per share, now owning 18.70% of ARAY. Accuray, a radiation oncology company, has a market cap of $31.3M and faces severe financial distress, with a Piotroski F-Score of 1 and an Altman Z-Score of -0.69. TCW Group's total equity holdings are valued at $14.87B, with a portfolio preference for technology and industrials.

Accuray Inc. amended a major shareholder report, detailing a $55M issuance of Series A Convertible Preferred Stock to investors, including affiliates of the reporting person. The deal involves $15M in cash and $40M in debt conversion, with warrants issued as incentives. The transaction is subject to closing conditions and stockholder approval. If not approved, a $15M fee is payable. The Series A Preferred Stock is convertible into common stock at $0.50 per share. TCW Asset Management gains board

Accuray (ARAY) reported a 21% revenue decline to $100.9M in Q4 2026, with China's market contributing to a 42% drop in product revenue. The company secured $60M in financing from TCW Asset Management, improving its balance sheet. Service revenue grew 6%, and cost savings exceeded targets. However, Accuray did not provide 2027 guidance due to trade policy uncertainties.

Accuray (ARAY) reported Q4 2026 revenue of $100.9M, down 21% YoY, with product revenue declining 42% due to geopolitical tensions. Service revenue grew 6% to $60.1M. Full-year revenue was $401.9M, down 12%. The company realized $20M in cost savings and expects $15M more in FY27. Adjusted EBITDA was $12.9M, up from $9.4M YoY. Management cited trade policy uncertainty and regional volatility as risks.